Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3368 - Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment

Date

08 Oct 2016

Session

Poster Display

Presenters

Yewon Kang

Citation

Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375

Authors

Y. Kang1, S. Seo2, J.Y. Hong2, D.H. Yoon2, S. Kim2, J.S. Park2, J. Huh3, S. Lee4, J. Ryu5, C. Suh2

Author affiliations

  • 1 Department Of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 3 Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 4 Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5 Department Of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
More

Resources

Abstract 3368

Background

Although serum beta-2 microglobulin (B2M) has been suggested as a potential prognostic predictor for patients with extranodal natural killer/T cell lymphoma (ENKTL), there are no prognostic models using B2M. We aimed to investigate the prognostic role of B2M by incorporating B2M into the most recently prognostic models, Prognostic Index of Natural Killer Lymphoma (PINK) and PINK-E (Epstein- Barr virus).

Methods

Between January 2005 to December 2014, 141 patients with ENKTL were identified in the database of the Asan Medical Center, Lymphoma Registry. Among them, 108 patients were treated with non-anthracycline based treatment.

Results

Median B2M value was 2.45 mg/L (range, 1.0-22.0) and baseline B2M was elevated in patients (45.4%). With median follow-up duration of 32.1 months (range, 0.3-131.0), and median overall survival (OS) was not reached. In univariate analysis, elevated B2M level was significantly associated with poorer OS (HR = 3.66; 95% CI: 1.96-6.82; p 

Conclusions

For ENKTL patients treated with non-anthracycline based therapy, we suggest a new prognostic index, consisting of age, stage, distant node involvement, non-nasal type disease and serum B2M, which could be good for discriminating poor risk groups and convenient to apply real practice.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings